Back to search results

A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC

Abroad (travel likely)RecruitingPHASE2

Conditions

Head and Neck Squamous Cell Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Moffitt Cancer Center, Tampa, Florida, United States

    Contact: Study coordinator (Kara Hoffman) · kara.hoffman@moffitt.org · 813-745-6020
    Contact: Principal Investigator (Christine Chung, MD)
    Kedar Kirtane, MD (Sub-investigator)
    Julie Kish, MD (Sub-investigator)
    Guilherme Rabinowits, MD (Sub-investigator)
Study leads

  • Christine Chung, MD

    Principal Investigator

    Moffitt Cancer Center

View source on ClinicalTrials.gov(opens in a new tab)